# Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia

> **NCT04319900** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Beijing Chao Yang Hospital** · enrollment: 150 (estimated)

## Conditions studied

- Novel Coronavirus Pnuemonia

## Interventions

- **DRUG:** favipiravir tablets+chloroquine phosphatetablets tablets
- **DRUG:** Favipiravir tablets
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04319900
- **Lead sponsor:** Beijing Chao Yang Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-05
- **Primary completion:** 2020-04-30
- **Final completion:** 2020-06-25
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2020-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04319900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04319900, "Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04319900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*